SLC26A4 and hearing loss disorder: Our study illustrates the feasibility of gene therapy for pendrin-related hearing loss, suggests differences in the pendrin requirement for the cochlea and the vestibular labyrinth, and suggest that sudden, fluctuating and progressive hearing loss can be the result of insufficient pendrin expression even when no enlargement of the membranous labyrinth is observed.